Tumor abnormality-oriented nanomedicine design
Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …
[HTML][HTML] Exploiting innate immunity for cancer immunotherapy
M Yi, T Li, M Niu, Q Mei, B Zhao, Q Chu, Z Dai, K Wu - Molecular cancer, 2023 - Springer
Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …
However, most of these immunomodulatory strategies focus on harnessing adaptive …
Immunogenic PANoptosis‐Initiated Cancer Sono‐Immune Reediting Nanotherapy by Iteratively Boosting Cancer Immunity Cycle
L Zhou, J Lyu, F Liu, Y Su, L Feng… - Advanced …, 2024 - Wiley Online Library
The cancer‐immune cycle conceptualized the mechanisms of driving T cell responses to
tumors, but w as limited by immunological ignorance elicited by tumor inherent …
tumors, but w as limited by immunological ignorance elicited by tumor inherent …
Targeting the Siglec–sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma
Glioblastoma (GBM) is the most aggressive form of primary brain tumor, for which effective
therapies are urgently needed. Cancer cells are capable of evading clearance by …
therapies are urgently needed. Cancer cells are capable of evading clearance by …
[HTML][HTML] Siglec receptors as new immune checkpoints in cancer
MA Stanczak, H Läubli - Molecular Aspects of Medicine, 2023 - Elsevier
Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies
has improved the treatment and prognosis of many patients. Nevertheless, most cancers are …
has improved the treatment and prognosis of many patients. Nevertheless, most cancers are …
Targeted glycan degradation potentiates cellular immunotherapy for solid tumors
J Wu, X Wang, Y Huang, Y Zhang… - Proceedings of the …, 2023 - National Acad Sciences
Immune cell–based cancer therapies, such as chimeric antigen receptor T (CAR-T)-cell
immunotherapy, have demonstrated impressive potency against hematological tumors …
immunotherapy, have demonstrated impressive potency against hematological tumors …
[HTML][HTML] Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment
H Egan, O Treacy, K Lynch, NA Leonard, G O'Malley… - Cell Reports, 2023 - cell.com
Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune
responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated …
responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated …
[HTML][HTML] Roles of glycosylation at the cancer cell surface: opportunities for large scale glycoproteomics
Cell surface glycosylation has a variety of functions, and its dysregulation in cancer
contributes to impaired signaling, metastasis and the evasion of the immune responses …
contributes to impaired signaling, metastasis and the evasion of the immune responses …
[HTML][HTML] Gut microbial structural variation associates with immune checkpoint inhibitor response
R Liu, Y Zou, WQ Wang, JH Chen, L Zhang… - Nature …, 2023 - nature.com
The gut microbiota may have an effect on the therapeutic resistance and toxicity of immune
checkpoint inhibitors (ICIs). However, the associations between the highly variable genomes …
checkpoint inhibitors (ICIs). However, the associations between the highly variable genomes …
[HTML][HTML] Immunomodulatory glycomedicine: Introducing next generation cancer glycovaccines
Cancer remains a leading cause of death worldwide due to the lack of safer and more
effective therapies. Cancer vaccines developed from neoantigens are an emerging strategy …
effective therapies. Cancer vaccines developed from neoantigens are an emerging strategy …